Compare drug alternatives
Soliqua® Alternatives
Soliqua®(Insulin Glargine And Lixisenatide) | Segluromet®(Ertugliflozin And Metformin Hydrochloride) |
|---|---|
Prescription Only | Prescription Only |
| Dosage & Administration | Dosage & Administration comparison data |
Administration | |
Oral . Learn more. | |
Dosing | |
Maximum recommended dose is 7.5 mg ertugliflozin/1,000 mg metformin twice daily. Take twice daily with meals, with gradual dose escalation. Do not use in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m2 . . Learn more. | |
Latin Shorthand | |
Max dose: 7.5 mg ertugliflozin / 1000 mg metformin BID. Take with meals, gradual dose increase. Avoid if eGFR < 30 mL/min/1.73 m².. Learn more. | |
| Financial Assistance | Financial Assistance comparison data |
Out-Of-Pocket Costs With Copay Card | |
$0. Learn more. | |
Annual Cap | |
$583 per fill . Learn more. | |
Assistance Expiration | |
12 uses. Learn more. | |
Generics | |
No lower-cost generic available | No lower-cost generic available |
| Physician Advisory | Physician Advisory comparison data |
Adverse Reactions | |
The most common adverse reactions, reported in ≥5% of patients treated with
SOLIQUA 100/33 include hypoglycemia, nausea, nasopharyngitis, diarrhea, upper
respiratory tract infection, and headache.. Learn more. | Most common adverse reactions associated with ertugliflozin
(incidence ≥5%) were female genital mycotic infections.
Most common adverse reactions associated with metformin
(incidence ≥5%) were diarrhea, nausea, vomiting, flatulence,
abdominal discomfort, indigestion, asthenia, and headache. . Learn more. |
Mechanism of Actions (MoA) | |
SGLT2 Inhibitors. Learn more. | |
Special Populations | |